AC Immune (NASDAQ:ACIU) Stock Rating Upgraded by StockNews.com

AC Immune (NASDAQ:ACIU) was upgraded by equities researchers at StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Wednesday.

Separately, HC Wainwright reiterated a “buy” rating and set a $16.00 price objective on shares of AC Immune in a research report on Friday, March 15th.

AC Immune Price Performance

Shares of ACIU stock traded down $0.03 during trading hours on Wednesday, hitting $2.35. The stock had a trading volume of 138,032 shares, compared to its average volume of 169,790. The stock has a market capitalization of $232.42 million, a price-to-earnings ratio of -3.31 and a beta of 1.05. AC Immune has a one year low of $1.90 and a one year high of $5.14. The stock’s 50-day moving average price is $2.92 and its two-hundred day moving average price is $3.32.

AC Immune (NASDAQ:ACIU) last released its quarterly earnings results on Thursday, March 14th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.01. The company had revenue of $16.71 million during the quarter, compared to analysts’ expectations of $16.36 million. As a group, equities research analysts predict that AC Immune will post -0.74 earnings per share for the current fiscal year.

Institutional Trading of AC Immune

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ACIU. Avidity Partners Management LP raised its position in AC Immune by 2.3% in the 3rd quarter. Avidity Partners Management LP now owns 2,969,800 shares of the company’s stock worth $8,464,000 after purchasing an additional 66,522 shares during the period. China Universal Asset Management Co. Ltd. purchased a new stake in AC Immune in the 4th quarter worth about $48,000. Nixon Peabody Trust Co. bought a new position in AC Immune in the 4th quarter worth about $64,000. Platinum Investment Management Ltd. grew its stake in AC Immune by 14.6% in the 4th quarter. Platinum Investment Management Ltd. now owns 1,515,585 shares of the company’s stock worth $7,578,000 after acquiring an additional 193,123 shares in the last quarter. Finally, BVF Inc. IL grew its stake in AC Immune by 96.2% in the 4th quarter. BVF Inc. IL now owns 14,571,236 shares of the company’s stock worth $72,856,000 after acquiring an additional 7,142,857 shares in the last quarter. 51.36% of the stock is owned by hedge funds and other institutional investors.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.